MBRX - Moleculin Biotech, Inc.
| Previous Close | 1.3700 |
| Open | 1.3900 |
| Bid | 1.37 x 1800 |
| Ask | 1.48 x 4000 |
| Day's Range | 1.3701 - 1.4200 |
| 52 Week Range | 0.9340 - 3.3400 |
| Volume | 56,971 |
| Avg. Volume | 336,488 |
| Market Cap | 38.524M |
| Beta (3Y Monthly) | 1.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.50 |
| Earnings Date | Apr 3, 2019 - Apr 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
- GlobeNewswire•2 days ago
Moleculin Announces Dr. James L. Abbruzzese, Chief of Medical Oncology Division at Duke University, Joins Science Advisory Board
Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that Dr. James L. Abbruzzese, Chief of Oncology at Duke University has joined Moleculin’s Science Advisory Board. “We are honored to have Dr. Abbruzzese, a distinguished medical oncologist join our Science Advisory Board,” commented Walter Klemp, Moleculin’s Chairman and CEO.
- GlobeNewswire•10 days ago
Moleculin Announces Patient Recruitment Begins in Annamycin Clinical Trial In Poland
Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has begun in Poland recruiting patients in the Company’s second clinical trial to study Annamycin for the treatment of relapsed and refractory adults with acute myeloid leukemia (“AML”).
- Zacks•11 days ago
Amarin Down on Lower '19 View, Posts Preliminary '18 Results
Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.
- GlobeNewswire•16 days ago
Moleculin Announces Positive Data for its Pancreatic Cancer Drug Candidate
Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that in preliminary animal studies, a second of its lead drugs, WP1732, has demonstrated enhanced activity in combination with checkpoint blockade antibodies in pancreatic cancer.
- GlobeNewswire•19 days ago
Report: Exploring Fundamental Drivers Behind Cronos Group, Henry Schein, Argo Group International, Eiger BioPharmaceuticals, China Automotive, and Moleculin Biotech — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Dec. 31, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: NeuroMetrix and Moleculin
NEW YORK, NY / ACCESSWIRE / December 12, 2018 / NeuroMetrix and Moleculin were both up almost 19% in Tuesday’s trading session. Traders were gearing up for Moleculin’s conference call today discussing a recent discovery of a use of one of its molecules for cancer treatment while NeuroMetrix announced an update on its strategic collaboration with GSK Consumer Healthcare. NeuroMetrix, Inc. shares were up nearly 19% on almost 1.7 million shares traded on Tuesday.
- GlobeNewswire•last month
REMINDER: Moleculin Announces Conference Call to Discuss Recent Breakthrough Discovery and FDA Filing on Wednesday, December 12, 2018
Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced a reminder it will host a conference call to discuss the recent discovery of a use of one of its molecules for cancer treatment and provide a business update. Participants can dial (800) 860-2442 or (412) 858-4600 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the Company's website at www.moleculin.com. A webcast replay will be available in the Investors section of the Company’s website at www.moleculin.com for 90 days.
- GlobeNewswire•last month
Moleculin Announces Conference Call to Discuss FDA Filing and New Immune Checkpoint Data on Wednesday, December 12, 2018
Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it will host a conference call to discuss the recent discovery of a use of one its molecule for cancer treatment and provide a business update. Participants can dial (800) 860-2442 or (412) 858-4600 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the Company's website at www.moleculin.com. A webcast replay will be available in the Investors section of the Company’s website at www.moleculin.com for 90 days.
- GlobeNewswire•last month
Moleculin Announces FDA Filing for Orphan Drug Designation for Glioblastoma Drug
Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has filed a request with the U.S. Food and Drug Administration (“FDA”) for Orphan Drug Status for its drug candidate WP1066.
- GlobeNewswire•2 months ago
Moleculin Announces Breakthrough Discovery for its WP1066
Walter Klemp, Moleculin’s Chairman and CEO added, “This potential was initially reported in a 2017 Japanese study (Journal of clinical and experimental hematopathology, Vol. 57 No.1, 21-25, 2017), but we have now been able to confirm this activity with our own sponsored research at MD Anderson. Also, very recent independent research (Front Pharmacol.
- GlobeNewswire•2 months ago
Moleculin Announces New Data Further Supporting Its Lead Drug for Treating Pancreatic Cancer
Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that data from an independent test in animal models confirmed, as previously believed, that its immuno-stimulating STAT3 inhibitor achieves disproportionately high accumulation in the pancreas. Walter Klemp, Moleculin’s Chairman and CEO added, “Published research shows that the growth and survival of pancreatic cancer requires activated STAT3 (p-STAT3) and our own research suggests that WP1732 may be one of the most effective inhibitors of p-STAT3 that has demonstrated activity in in vivo models. Confirming the disproportionately high accumumulation of WP1732 in the pancreas puts us one step closer to introducing an entirely new approach to treating pancreatic cancer. This is very encouraging and confirms the direction that Moleculin has taken with WP1732.
- GlobeNewswire•2 months ago
Moleculin Requests FDA Meeting Regarding IND for New Cancer Drug
Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has filed a request with the US Food and Drug Administration (FDA) for a Pre-Investigational New Drug (IND) Meeting to seek FDA’s guidance and concurrence that the WP1732 development plan will meet requirements for an Initial IND filing and initiation of a proposed Phase 1 clinical trial.
- GlobeNewswire•2 months ago
Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2018
Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, today announced its financial results for the third quarter ended September 30, 2018. Additionally, the Company announced potential upcoming milestones and recent corporate developments. Walter Klemp, Chairman and CEO of Moleculin, said, “We maintain a sharp focus on the continuing development of our broad-based oncology portfolio and in effectively advancing those solutions through the FDA regulatory process.
- GlobeNewswire•3 months ago
Moleculin Announces Significant Milestone Achieved in Glioblastoma Trial
Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced positive progress in the Phase 1 clinical trial of its immuno-stimulating STAT3 inhibitor, WP1066, with initial results showing bioavailability of the drug in patients. Walter Klemp, Moleculin’s Chairman and CEO added, “We believe WP1066 is a first-in-class compound capable of stimulating a natural immune response in animal models while directly attacking tumors by modulating transcriptional activity and repressing what we call ‘oncogenic transcription factors.’ Chief among these is STAT3, considered a master regulator of tumor progression. While activity in animal models has been very promising, one of the goals of this trial was to determine the potential for bioavailability in humans. The initial positive indications of this clinical trial increase our confidence that WP1066 has the potential to become an important drug in the treatment of certain cancers.
- GlobeNewswire•3 months ago
Moleculin Announces Positive Data on WP1066 in Pre-Clinical Trials
Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that investigators at Emory University will present animal model data supporting the potential of WP1066 to treat pediatric brain tumors at the upcoming Society for Neuro-Oncology Annual Scientific Meeting.
